ConductScience.org, home

Comparison · NCT03070184-sae

Black Participants vs White Participants: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Black Participants vs White Participants: serious adverse events. Trial comparisons, record NCT03070184-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03070184-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.0876wilson
Risk in group 2000.0876wilson
Risk difference, group 1 minus group 20-0.08760.0876newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Black Participants
Healthy lean (BMI 18-25 kg/m2) African-American participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will perform exercise capacity VO2 max determination test, followed by 3 days of standardized meals and exercise challenge test. After exercise challenge test, all the participants will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day.~Exercise capacity VO2 max determination: Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol.~Standardized meals: Participants will consume the standardized study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).~Exercise challenge: Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill.~Metoprolol Succinate ER: Each participant will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day for total duration of 6 weeks.
040EG000
Group 2White Participants
Healthy lean (BMI 18-25 kg/m2) white participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will perform exercise capacity VO2 max determination test, followed by 3 days of standardized meals and exercise challenge test. After exercise challenge test, all the participants will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day.~Exercise capacity VO2 max determination: Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol.~Standardized meals: Participants will consume the standardized study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).~Exercise challenge: Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill.~Metoprolol Succinate ER: Each participant will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day for total duration of 6 weeks.
040EG001

Harm

What it counts
Total, serious adverse events
Time frame
Adverse events were collected after the completion of the screening visit, during the exercise visits, and during the Beta-Blocker intervention period for a total of 14 weeks

Source ClinicalTrials.gov

Trial

Title
Race, Natriuretic Peptides and Physiological Perturbations
NCT number
NCT03070184
Phases
PHASE2
Conditions
Healthy, Pre Hypertension
Interventions
Exercise capacity VO2 max determination, Standardized meals, Exercise challenge, Metoprolol Succinate ER
Lead sponsor
University of Alabama at Birmingham
Results first posted
2025-02-27

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03070184-sae